Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study

Background: NEPA is an oral fixed-dose combination of netupitant, a new highly selective neurokinin-1 receptor antagonist, and palonosetron. This study was conducted to evaluate whether the efficacy of NEPA against chemotherapy-induced nausea and vomiting (CINV) in cycle 1 would be maintained over s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC cancer 2020-03, Vol.20 (1), p.232-232, Article 232
Hauptverfasser:	Caputo, Roberta, Cazzaniga, Marina Elena, Sbrana, Andrea, Torrisi, Rosalba, Paris, Ida, Giordano, Monica, Montesarchio, Vincenzo, Guarneri, Valentina, Amaducci, Laura, Bilancia, Domenico, Cilenti, Giuseppina, Fabi, Alessandra, Collova, Elena, Schirone, Alessio, Bonizzoni, Erminio, Celio, Luigi, De Placido, Sabino, De Laurentiis, Michelino
Format:	Artikel
Sprache:	eng
Schlagworte:	Anthracycline Anthracyclines Anxiety Breast cancer Cancer patients Cancer research Cancer therapies Cancer treatment Care and treatment Chemotherapy CINV Clinical medicine Cyclophosphamide Dexamethasone Drug dosages Gastrointestinal agents Glucocorticoids Hypotheses Life Sciences & Biomedicine Medical research Nausea NEPA Oncology Palonosetron Patients Science & Technology Steroids Survival Vomiting
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!